现代膀胱癌症管理中的三联疗法 - Suppr

Suppr

超能文献

Trimodality therapy in the modern era for management of bladder cancer.

作者信息

Wang Shang-Jui

机构信息

Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

出版信息

Transl Cancer Res. 2024 Aug 31;13(8):3935-3939. doi: 10.21037/tcr-24-262. Epub 2024 Aug 20.

DOI:10.21037/tcr-24-262

PMID:39262470

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11385536/

Abstract

摘要

相似文献

Trimodality therapy in the modern era for management of bladder cancer.现代膀胱癌症管理中的三联疗法

Transl Cancer Res. 2024 Aug 31;13(8):3935-3939. doi: 10.21037/tcr-24-262. Epub 2024 Aug 20.

Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.免疫和基质浸润对肌层浸润性膀胱癌保膀胱三联疗法后结局的影响。

Eur Urol. 2019 Jul;76(1):59-68. doi: 10.1016/j.eururo.2019.01.011. Epub 2019 Feb 1.

Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions.肌肉浸润性膀胱癌的三联疗法：最新进展与未解决的问题

Curr Oncol Rep. 2020 Feb 1;22(2):14. doi: 10.1007/s11912-020-0880-5.

Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.根治性膀胱切除术与肌肉浸润性膀胱癌的保留器官三联疗法：一项临床试验的系统评价

Crit Rev Oncol Hematol. 2015 Sep;95(3):387-96. doi: 10.1016/j.critrevonc.2015.04.006. Epub 2015 Apr 17.

Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.肌层浸润性膀胱癌患者三联疗法的预测因素及其对生存的影响。

Clin Transl Oncol. 2024 Feb;26(2):446-455. doi: 10.1007/s12094-023-03264-9. Epub 2023 Jun 30.

Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.三联疗法与新辅助化疗联合根治性膀胱切除术治疗肌层浸润性膀胱癌的生存比较：基于人群的分析。

Eur J Med Res. 2023 Oct 11;28(1):422. doi: 10.1186/s40001-023-01408-9.

Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis.比较接受根治性膀胱切除术和膀胱保留三联疗法的肌层浸润性膀胱癌患者的长期生存结果：一项多中心队列分析。

J Oncol. 2022 May 14;2022:7306198. doi: 10.1155/2022/7306198. eCollection 2022.

Trimodality bladder preservation therapy for muscle-invasive bladder cancer.三模态膀胱癌保留膀胱治疗。

J Natl Compr Canc Netw. 2013 Aug;11(8):952-60. doi: 10.6004/jnccn.2013.0116.

Trimodality therapy for bladder preservation in the elderly population with invasive bladder cancer.老年浸润性膀胱癌患者的膀胱保留三联疗法。

Front Oncol. 2014 Aug 5;4:206. doi: 10.3389/fonc.2014.00206. eCollection 2014.

Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy.MRE11 分析与接受三联疗法治疗的肌肉浸润性膀胱癌成人患者的死亡率。

JAMA Netw Open. 2022 Nov 1;5(11):e2242378. doi: 10.1001/jamanetworkopen.2022.42378.

本文引用的文献

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024).非转移性肌层浸润性膀胱癌的治疗：美国泌尿外科学会/美国临床肿瘤学会/美国泌尿外科学会指南（2017年；2020年、2024年修订）

J Urol. 2024 Jul;212(1):3-10. doi: 10.1097/JU.0000000000003981. Epub 2024 Apr 25.

Quality of life after definitive treatment for bladder cancer: A systematic review and meta-analysis.膀胱癌根治性治疗后生活质量的系统评价和荟萃分析。

Radiother Oncol. 2024 Jan;190:110038. doi: 10.1016/j.radonc.2023.110038. Epub 2023 Nov 30.

Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study.根治性膀胱切除术与膀胱保留治疗肌层浸润性膀胱癌患者的无病生存率：一项全国性研究。

Int J Radiat Oncol Biol Phys. 2024 Jan 1;118(1):41-49. doi: 10.1016/j.ijrobp.2023.07.027. Epub 2023 Jul 28.

Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer.对于临床淋巴结阳性非转移性膀胱癌患者，根治剂量放疗的保膀胱治疗是根治性膀胱切除术的有效替代方法。

J Clin Oncol. 2023 Sep 20;41(27):4406-4415. doi: 10.1200/JCO.23.00725. Epub 2023 Jul 21.

Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.根治性膀胱切除术与三联疗法治疗肌层浸润性膀胱癌：多机构倾向评分匹配和加权分析。

Lancet Oncol. 2023 Jun;24(6):669-681. doi: 10.1016/S1470-2045(23)00170-5. Epub 2023 May 12.

Bladder Preservation for Muscle-Invasive Bladder Cancer With Variant Histology.保留膀胱治疗具有变异组织学的肌层浸润性膀胱癌。

Semin Radiat Oncol. 2023 Jan;33(1):62-69. doi: 10.1016/j.semradonc.2022.10.008.

Current best practice for bladder cancer: a narrative review of diagnostics and treatments.当前膀胱癌的最佳实践：诊断和治疗的叙述性综述。

Lancet. 2022 Nov 12;400(10364):1712-1721. doi: 10.1016/S0140-6736(22)01188-6. Epub 2022 Sep 26.

Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.肌层浸润性膀胱癌的放化疗：3 期随机对照 BC2001 试验的 10 年随访结果。

Eur Urol. 2022 Sep;82(3):273-279. doi: 10.1016/j.eururo.2022.04.017. Epub 2022 May 14.

Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399).根治性放化疗联合生物标志物分层的缺氧修饰治疗的长期结果：膀胱癌 Carbogen 烟酰胺（BCON）3 期随机试验（ISRCTN45938399）的 10 年更新。

Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1407-1415. doi: 10.1016/j.ijrobp.2021.03.001. Epub 2021 Mar 6.

Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials.局部晚期膀胱癌的分割放疗：BC2001 和 BCON 试验的个体患者数据分析荟萃分析。

Lancet Oncol. 2021 Feb;22(2):246-255. doi: 10.1016/S1470-2045(20)30607-0.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验